Does Blue Cross Blue Shield of North Carolina Cover Cialis?

Tadalafil, sold under the brand name Cialis, belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors. In 2003, the FDA approved Cialis to treat erectile dysfunction, followed by approval of a 5 mg daily dose for benign prostatic hyperplasia in 2011. Following a patent settlement between Eli Lilly and generic drugmakers, generic versions of tadalafil entered the U.S. market in 2018 (FDA application record). The same active ingredient is available as Adcirca, which is prescribed for pulmonary arterial hypertension using different dosing guidelines and insurance coverage criteria than Cialis.

The question most Blue Cross Blue Shield of North Carolina (BCBSNC) members actually need answered is not "does BCBSNC cover Cialis," because brand-name Cialis is rarely the product that gets dispensed once a generic exists. The real question is whether BCBSNC covers generic tadalafil, under which diagnosis code, and with what prior authorization or step therapy hurdles attached. Those answers differ by plan type (commercial, ACA marketplace, Medicare Advantage) and by indication (ED versus BPH), and they are the parts of this page that require direct verification against your specific plan document, because insurer formularies change and HealthRX.com has no first-party access to BCBSNC's live plan data.

Core answer, with its boundary: Brand-name Cialis is commonly excluded or placed on a non-preferred tier across BCBSNC plan types, while generic tadalafil is more often covered with prior authorization, step therapy, and quantity limits; Medicare Part D statutorily excludes drugs used for sexual or erectile dysfunction, but tadalafil 5 mg daily prescribed solely for BPH is a separate, sometimes-covered pathway. This pattern is consistent with how PDE5 inhibitor coverage functions across U.S. commercial insurers generally, but the exact tier, copay, and prior authorization criteria for any individual BCBSNC plan cannot be confirmed by a general reference page and must be checked through the plan's own formulary tool or Member Services line.

What is established versus what needs plan-level verification

Established, and stable across time:

• Tadalafil is FDA-approved for ED, for BPH (5 mg daily), and, as Adcirca, for pulmonary arterial hypertension. These are separate approvals with separate prescribing information (FDA label).
• The FDA requires generic tadalafil to demonstrate bioequivalence to brand Cialis, meaning the same active ingredient, strength, dosage form, and rate of absorption (as described in FDA guidance on generic drug approval standards).
• Medicare Part D, by federal statute, excludes coverage of drugs used for the treatment of sexual or erectile dysfunction. CMS guidance on Part D drug coverage exclusions describes this category directly (CMS, Medicare prescription drug coverage).
• The American Urological Association's 2018 guideline lists PDE5 inhibitors as first-line pharmacologic therapy for men with ED who have no contraindication (AUA ED guideline, 2018). The AUA's BPH/LUTS guideline separately lists tadalafil 5 mg daily as an evidence-based option for lower urinary tract symptoms attributed to BPH (per AUA guideline recommendations on lower urinary tract symptoms attributed to BPH).
• Pooled trial data support tadalafil 5 mg daily improving International Prostate Symptom Score (IPSS) versus placebo over 12 weeks in men with BPH (a pooled analysis of randomized trials of tadalafil for BPH-related lower urinary tract symptoms).
• In the original PDE5 inhibitor efficacy trial for ED, sildenafil produced meaningfully higher rates of successful intercourse attempts than placebo (the original placebo-controlled trial establishing PDE5 inhibitor efficacy for ED); this establishes the drug class's efficacy rationale but does not itself describe BCBSNC's coverage rules.

Plausible but not verifiable from the sources on this page, and therefore flagged for verification:

• The specific tier placement (Tier 2 vs. Tier 3 vs. exclusion) of tadalafil on any given BCBSNC commercial, ACA, or Medicare Advantage plan. Formularies are plan-specific and change on a quarterly or annual cycle. A prior BCBSNC formulary listing is a snapshot in time, not a durable fact.
• Exact copay or coinsurance dollar amounts. Cost-sharing depends on the member's specific benefit design, deductible status, and plan year.
• Aggregate figures such as total BCBSNC membership counts, or precise percentages for prior authorization denial and appeal-overturn rates. The reference list below includes studies that examined PDE5 inhibitor coverage and prior authorization patterns in commercially insured populations, but this page cannot confirm the exact percentages those studies reported without the full text in hand, and BCBSNC-specific denial rates are not published in these sources at all. Treat any specific percentage as illustrative of a documented pattern in the literature, not as a BCBSNC-specific figure, until verified.
• Quotations attributed to individual physicians on ED as a medical condition. No verifiable, attributable quotation was available in the source material for this page, so no quotation is presented here. The underlying clinical position, that ED has recognized organic causes and PDE5 inhibitors are appropriate first-line therapy, is supported directly by the AUA guideline citation above.

Not established:

• That North Carolina law mandates ED drug coverage. It does not. ED medications fall outside the state's Essential Health Benefit benchmark for ACA marketplace plans.
• That SSRI-induced sexual dysfunction is reliably covered as a mental health parity matter in North Carolina. This is a plausible legal argument raised in appeals, not a settled coverage rule, and it has not been broadly tested in NC courts.

How BCBSNC's tiering approach likely works, and why it varies

BCBSNC organizes prescription drugs into cost-sharing tiers. Generic drugs, including generic tadalafil, are ordinarily placed at a lower tier than brand-name equivalents once a bioequivalent generic exists, because the wholesale acquisition cost of a generic PDE5 inhibitor is substantially lower than the brand product. This general tiering logic is standard formulary design across commercial insurers and is not unique to BCBSNC, but the exact tier number assigned to tadalafil on your plan is not something a general article can state with confidence. Confirm it through BCBSNC's member portal formulary search tool for your specific plan ID, since formulary placement is updated on a recurring cycle and can shift at renewal.

Whether your plan is employer-sponsored commercial, an ACA marketplace product (such as Blue Local or Blue Select), or a Medicare Advantage plan changes the coverage picture substantially, because these product lines are governed by different regulatory frameworks:

• Commercial employer-sponsored plans have the broadest discretion. Employers choose benefit designs, and some self-funded employers exclude ED medications as a category regardless of what BCBSNC's standard formulary would otherwise allow.
• ACA marketplace plans must cover Essential Health Benefits, but ED medications are not part of North Carolina's EHB benchmark, so their inclusion is the insurer's or plan's choice, not a federal requirement.
• Medicare Advantage (Blue Medicare) plans follow Part D rules, which statutorily exclude ED-indicated drugs, but permit coverage of tadalafil 5 mg daily when the documented indication is BPH rather than ED.

Prior authorization: what is typically required

BCBSNC plans that cover tadalafil for ED commonly require prior authorization before the pharmacy will dispense it. Based on standard PDE5 inhibitor prior authorization criteria used across commercial insurers, and consistent with the AUA's first-line therapy guidance, expect the request to need:

• A confirmed ED diagnosis (ICD-10 N52.x)
• Documentation that no absolute contraindication exists, most importantly concurrent nitrate use, which is an established drug interaction risk with PDE5 inhibitors
• In many plans, evidence that a different PDE5 inhibitor (commonly sildenafil) was tried first, unless a clinical reason supports skipping that step (step therapy exception)

Standard versus urgent review timelines, exact quantity limits, and whether a given plan requires step therapy at all are plan-specific details that should be confirmed directly with BCBSNC rather than assumed from general industry patterns.

The BPH pathway: a real but narrow route to coverage

Because Medicare Part D and some commercial or marketplace plans exclude ED-indicated drugs, a documented BPH diagnosis is a legitimate, separate coverage pathway for tadalafil 5 mg daily, supported by FDA approval and AUA guideline inclusion for BPH/LUTS management. This pathway is appropriate only when the patient genuinely has BPH symptoms warranting treatment. Many men over 50 have both ED and BPH, and a prescriber can document BPH as the primary indication when clinical evidence, such as an elevated IPSS score, supports it. Using this pathway solely to route around an ED exclusion without a genuine BPH diagnosis is not something this page recommends and would not be a defensible basis for a prior authorization request.

What you will likely pay, and why exact numbers are not stated here

Out-of-pocket cost for tadalafil under a BCBSNC plan depends on tier placement, deductible status, and whether the pharmacy fills a generic or, rarely, a brand product. General market patterns (confirmed through commonly cited retail and discount pharmacy pricing as of 2025-2026) show that generic tadalafil is dramatically cheaper than brand Cialis, and that cash-pay generic pricing through discount programs or telehealth platforms can, for some members, be lower than an insurance copay would have been. Because exact copay amounts are plan-specific and dollar figures are volatile, use BCBSNC's cost estimator tool or ask Member Services for your plan's specific tier cost-share rather than relying on a published range.

Appeals if coverage is denied

North Carolina law (N.C.G.S. § 58-50-75 through 58-50-95) gives insured members the right to an internal appeal followed by an independent external review through a certified Independent Review Organization, filed through the NC Department of Insurance, if BCBSNC's internal review upholds a denial. A well-supported appeal typically includes clinical notes, the AUA guideline's first-line therapy recommendation for PDE5 inhibitors, documentation of any failed alternative therapy, and relevant comorbidities. The exact response-time windows BCBSNC uses for standard and expedited appeals should be confirmed from the denial letter itself, since these can be plan-specific.

Alternatives if tadalafil is not covered

If a plan excludes tadalafil for ED and an appeal is unsuccessful, options include:

• Generic sildenafil, which may sit at a lower formulary tier with fewer restrictions and has a similar efficacy profile for many men, with a shorter duration of action (roughly 4 to 6 hours versus a longer window for tadalafil).
• Cash-pay generic tadalafil through retail discount programs or telehealth platforms, which for some members costs less than an insurance copay.
• Compounded formulations, which insurance does not cover, from a licensed compounding pharmacy, only when a prescriber determines a custom dose or form is clinically appropriate.

Tadalafil for pulmonary arterial hypertension: a separate track entirely

Tadalafil marketed as Adcirca for PAH follows its own specialty pharmacy and prior authorization pathway based on right heart catheterization data and WHO functional class, unrelated to ED coverage rules. Trial data in this population showed improved 6-minute walk distance with tadalafil 40 mg versus placebo (a randomized trial of tadalafil in pulmonary arterial hypertension). If tadalafil is prescribed for PAH, the ED-specific restrictions described above do not apply.

When to seek care rather than rely on this page

If you experience chest pain, a sudden change in vision or hearing, an erection lasting more than four hours, or symptoms suggestive of a cardiac event while considering or using a PDE5 inhibitor, seek urgent medical care rather than waiting on a coverage decision. Concurrent nitrate use with any PDE5 inhibitor is a contraindication that requires direct discussion with a prescriber, not self-management.

Verification checklist: stable facts versus facts you must confirm today

Use this to separate what you can trust from this page versus what only your plan documents can answer.

Stable, federal or clinical facts (do not need re-verification by date):

• Tadalafil is FDA-approved for ED, for BPH (5 mg daily), and, as Adcirca, for PAH.
• Generic tadalafil must be bioequivalent to brand Cialis under FDA rules.
• Medicare Part D statutorily excludes drugs used for sexual or erectile dysfunction.
• AUA guidelines list PDE5 inhibitors as first-line ED therapy and tadalafil 5 mg daily as an evidence-based BPH/LUTS option.
• Concurrent nitrate use is a contraindication with PDE5 inhibitors.

Date-sensitive facts you must confirm directly with BCBSNC or your pharmacy, not from this page:

• Current formulary tier for tadalafil on your specific plan (commercial, ACA, or Medicare Advantage)
• Whether prior authorization or step therapy applies to your plan this benefit year
• Current quantity limits for your prescribed dose and frequency
• Your plan's exact copay or coinsurance amount at your current deductible status
• Whether your plan covers tadalafil 5 mg daily under a BPH diagnosis if ED indications are excluded
• Current cash-pay pricing at your preferred pharmacy or telehealth platform, since retail and discount pricing changes

How to confirm: log into the BCBSNC member portal, search the formulary tool for "tadalafil," and call the Member Services number on your insurance card to ask directly whether your plan covers it for your specific diagnosis, and what prior authorization criteria apply. Ask your prescriber's office to run a real-time pharmacy benefits check as a second confirmation.